Trials / Completed
CompletedNCT01854437
The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 42 (actual)
- Sponsor
- Shiraz University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Hyperphosphatemia is a common problem in hemodialysis (HD) patients. Different chelators for control of Hyperphosphatemia are used. The aim of this study was to assess the effect of magnesium oxide (Mg Oxide) on the control of serum phosphorus (P) level and evaluation of its side effects in hemodialysis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mg Oxide | 250 mg orally for 4 weeks |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2013-05-15
- Last updated
- 2013-05-15
Locations
1 site across 1 country: Iran
Source: ClinicalTrials.gov record NCT01854437. Inclusion in this directory is not an endorsement.